Chronic rhinosinusitis with nasal polyps (CRSwNP) represents growing health problem in developed countries. Recent study reviled that topical furosemide is beneficial treatment for CRSwNP, reducing the recurrence of polyps after endoscopic sinus surgery. However, the optimal dosage and treatment duration has not been established and require further investigation. The article was published in JAMA Otolaryngology–Head & Neck Surgery. Read full text »
Chronic heart failure (CHF) is a progressive disease which manifests itself as a decrease in cardiac output accompanied with myocardial dysfunction. The most common cause of CHF is the ischemic heart disease (IHD) but it may also be a complication of hypertension, cardiomyopathy or myocarditis. Disease is characterized with high mortality, 50% of patients die within 5 years of diagnosis. Therefore the search for new therapeutic approaches, that could improve these statistics continues. Read full text »
An interdisciplinary group of scientists from Boston University School of Medicine has described a new protein named TMIGD1 that proved to be engaged into epithelial cells protection in the renal tubules. This particular protein in the future could become a target of new therapeutic strategies used in patients suffering from both acute and chronic kidney disease. Read full text »
Chronic fatigue syndrome (CFS) has been not only definitional problem, but also diagnostic and therapeutic one for medical world. Scientists from Center for Infection and Immunity and from Department of Epidemiology, Columbia University Mailman School of Public Health, New York in their latest report come closer to the solution. Read full text »
Since the introduction of recombinant human erythropoietin (rhEPO) to clinical practice it seemed that the problem of anaemia in patients with chronic kidney disease has been brought under control. Further years have produced modifications of particles of rhEPO and led to the synthesis of new medicines – erythropoiesis stimulating agents. These drugs are characterized by longer half-life and the stability of action. However, the results of recent clinical trials carry dangerous conclusions. Despite the improvement of morphological parameters, the reduction of mortality in these patients was not observed.
Nowadays, especially in industrial countries it is more common to hear about psychiatric disorders. There are more and more described neuro-psychatric diseases. An interesting disease is Chronic Fatigue Syndrome (CFS), first described in 1956 in England, and in the year 1988 it was recognized as individual syndrome by Center for Disease Control (CDC). Read full text »